The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
US listing only is my interpretation of that RNS which is is fine by me.
Just be glad to get it over and done with! Only takes a few mins to sign W-8BEN from with HL if you haven't already done so.
https://www.openaccessgovernment.org/novel-foods/107344/
The Novel Food Application referred to in the Sky article is a good thing. Quality products operating in a properly regulated market that people can trust.
Rest assured CBX know all about this as the Novel Food Application has been talked about for at least a year, it's just the deadline to submit your application.
I'm starting to question if/when it lists do I have faith in the BOD to manage its worldwide launch. If the last 6 months of TILS is anything to go by it's a no.
Would be delighted to eat my words at 7am tomorrow.
Old - could it be an investment / share issue so we've got some more cash to get things off the ground?
Physical - I remember that picture from last year at the height of the Accustem demerger. May have been that 'plumber' fellow from Twitter who posted it? If only....
Getting ahead of myself then. Topline data is what we've already had with detailed (bottom line?) data to follow ASAP.
These Redchip interviews aren't aimed at us lot usually, just a chance to spread the word to people who've never heard of Tiziana which is fine by me.
JH - So do you think this will be the Topline data he'll be talking about from the 2nd Feb RNS?
· Data on pharmacokinetics of nasally administered Foralumab, immunological biomarkers, stimulation of Tregs and anti-drug antibody ("ADA") is expected to be reported in a few weeks.
Was this mentioned in the call last night?
Taken from website:
Tiziana intends to initiate Phase 2b in HCC patients with Milciclib in combination with a TKI in Q2 2021.
Thanks Rockz
Nice one FFF, much appreciated
Someone mentioned sidekick. Who was on call from TILS apart from Dr K?
Afternoon all.
Wondering if others think TILS were cautiously light on the PR from Brazil until they had the full results? I'm no scientist but this is innovative and disruptive tech they have here and deserves more.
They're not usually shy when they've got something to shout about (Stemprinter/Exact Sciences for example) so was a little puzzled more of a fuss wasn't made.
2nd Feb RNS
· Data on pharmacokinetics of nasally administered Foralumab, immunological biomarkers, stimulation of Tregs and anti-drug antibody ("ADA") is expected to be reported in a few weeks.
Lolm - there's another video or RNS somewhere that mentions "a few weeks" from the preliminary results, that's next Tuesday if you take a few weeks a 3. I'll see if I can find it
lolmcshizz - next step...
https://youtu.be/eHui5s82bU0?t=518
Preliminary results 2 weeks ago today with full results inc. Pharmacokinetics, whatever they are, due within a "few weeks" from 2nd Feb.
I'll be wanting to see the results and a detailed plan for the next step either within the RNS or very closely afterwards.
B.Riley Inc £2.88
HC Wainright LLC £3.95
B Sapphire investment services £0.40
Seeing as Dr K and scientific team are US based I would expect they'll submit our trial findings to the relevant agencies over there rather than the UK government. Dr W mentioned further US trials and Dr K is just waiting to update the market on the "Perfect Plan".
Happy to wait and find out what this perfect plan is, just not too long though please!
Let's hope GC has got something up his sleeve, he's been quiet these last few days.
When I heard GC had taken up the Chaiman role at OKYO I did assume that either A*****em or TILS was in the process of being sold. Seemed odd to take that on as well when there's a whole new company to set up that shall not be named.